A Longitudinal Observational Study of the Natural History and Management of Patients With HCC (NCT02954094)
A Longitudinal Observational Study of the Natural History and Management of Patients With Hepatocellular Carcinoma
🩺 Plain-English Summary (8th-Grade Level)
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Who can join: Review the eligibility criteria below.
Location: Banner University Medical Center — Phoenix, Arizona
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (71 Sites)
Showing the first 25 of 71 sites.
- Banner University Medical Center — Phoenix, Arizona
- University of Arkansas — Little Rock, Arkansas
- University of Southern California/Norris Comprehensive Cancer Center — Los Angeles, California
- Stanford University — Palo Alto, California
- California Liver Research Institute — Pasadena, California
- University of California-Davis — Sacramento, California
- University of California — San Francisco, California
- Georgetown University — Washington D.C., District of Columbia
- Gastro Florida — Clearwater, Florida
- University of Florida Hepatology Research at CTRB — Gainesville, Florida
- University of Florida Health Gastroenterology — Jacksonville, Florida
- Schiff Center for Liver Diseases/University of Miami — Miami, Florida
- Tampa General Medical Group — Tampa, Florida
- Piedmont Atlanta Hospital — Atlanta, Georgia
- Piedmont Cancer Institute — Atlanta, Georgia
- Emory University Hospital — Atlanta, Georgia
- Northwestern University Division of Gastroenterology and Hepatology — Chicago, Illinois
- Rush University Medical Center — Chicago, Illinois
- University of Chicago — Chicago, Illinois
- University of Iowa Hospitals and Clinics — Iowa City, Iowa
- Tulane University — New Orleans, Louisiana
- Mercy Medical Center, GI Research — Baltimore, Maryland
- Johns Hopkins University — Baltimore, Maryland
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatocellular Cancer
- Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma — Bethesda, Maryland
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) — Duarte, California
Explore by condition: All Hepatocellular Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.